Technology
NetraAI. Built for the data trials actually produce.
Traditional analyses average across the entire population, missing the patient-level signals that determine whether a drug works. NetraAI is engineered to find those signals — and explain them.
The flow
From sponsor data to a protocol-ready trial strategy.
01
Sponsor data
Phase 1–3 trial datasets ingested securely under MSA.
02
NetraAI analysis
Proprietary AI identifies hidden subpopulations in small, noisy data.
03
Explainable subgroups
2–4 interpretable variables define each subgroup. Patient membership listed.
04
Trial strategy
Protocol/SAP-ready criteria for the next-phase trial design.
Proven results
A 4× improvement in effect size from two small eligibility changes.
In a previously failed Phase 2 readout, NetraAI identified two clinically interpretable refinements — removing subjects with a Baseline HAMD SS GI score of 0, and systolic BP 137–143 — transforming the trial signal into a meaningful treatment effect.
Phase 2 readout — depression
Treatment effect, refined cohort
| Visit | N | Cohen's d | p-value |
|---|---|---|---|
| Day 7 | 61 | 0.80 | 0.01 |
| Day 14 | 128 / 208 (62%) | 0.39 | 0.029 |
| Day 28 | 126 / 208 (61%) | 0.35 | 0.053 |
What changed
Two interpretable refinements.
- 01
Remove subjects with a Baseline Score of 0 on HAMD SS GI.
- 02
Remove subjects with Systolic BP between 137 and 143.
4×
Improvement in effect size vs. original analysis
Commercial model
Two routes to market.
Direct to sponsors
Phase 2 & Phase 3 readout analysis
- • C$250–350K per 6-week engagement
- • 40+ active opportunities in pipeline
- • 7+ proposals/contracts in progress
- • 10 repeat contracts with NASDAQ-listed biopharma client
Channel partners
CRO-embedded
- • Worldwide Clinical Trials — MSA executed, QA complete (Oct 2025)
- • NetraAI embedded in WCT Phase 2/3 bids across CNS and oncology
- • Scalable: included in CRO proposals as standard service
- • Additional CRO partnerships being explored